Personalized medicine trial offers new hope for Tough-to-Treat rare ovarian cancers
NCT ID NCT04931342
Summary
This study is testing several personalized treatments for women whose rare types of ovarian cancer have persisted or returned after prior therapy. Doctors will use specific markers found in a patient's tumor to match them to one of the investigational treatments. The main goal is to see if these targeted approaches can shrink tumors and control the disease for a meaningful period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. U. Consorziale Policlinico di Bari
Bari, Apulia, 70124, Italy
-
Adana Baskent University Medical Faculty; Oncology
Adana, 01220, Turkey (Türkiye)
-
Asan Medical Center
Seoul, 05505, South Korea
-
Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü
Ankara, 06490, Turkey (Türkiye)
-
CHU Besançon - Hôpital Jean Minjoz
Besançon, 25030, France
-
Cabrini Hospital
Malvern, Victoria, 3144, Australia
-
Centre Eugène Marquis
Rennes, 35042, France
-
Centre Francois Baclesse
Caen, 14076, France
-
Centre Leon Berard
Lyon, 69373, France
-
Groupe Hospitalier Diaconesses
Paris, 75020, France
-
Gustave Roussy
Villejuif, 94800, France
-
Gynekologicko-porodnicka klinika
Prague, 120 00, Czechia
-
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hôpitaux Universitaires de Genève
Geneva, 1205, Switzerland
-
ICO - Site René Gauducheau
Saint-Herblain, 44805, France
-
IRCCS S. Raffaele
Milan, Lombardy, 20132, Italy
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institutio Catalan De Oncologia
Barcelona, 08908, Spain
-
Istituto Tumori Napoli
Naples, Campania, 80131, Italy
-
Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie
Essen, 45136, Germany
-
Koc University Medical Faculty; Department of Gynecology & Obstetrics
Istanbul, 34010, Turkey (Türkiye)
-
LLC Medscan
Moskva, Moscow Oblast, 119421, Russia
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
McGill University Health Centre - Glen Site
Montreal, Quebec, H4A 3J1, Canada
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 1Z5, Canada
-
Samsung Medical Center
Seoul, (0)6351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Texas Oncology - Gulf Coast
The Woodlands, Texas, 77380, United States
-
UCSF Helen Diller Family CCC
San Francisco, California, 94158, United States
-
University College London Hospitals NHS Foundation Trust - University College Hospital
London, NW1 2PG, United Kingdom
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Universitätsklinikum Mannheim
Mannheim, 68167, Germany
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
Washington University School of Medicine
St Louis, Missouri, 63108, United States
-
Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
Conditions
Explore the condition pages connected to this study.